Back HIV/AIDS

HIV / AIDS

CROI 2014: Men Not Benefiting as Much as Women from HIV Treatment in Africa [VIDEO]

Scale-up of antiretroviral therapy (ART) has led to a much larger reduction in mortality for women than for men, according to a report presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

CROI 2014: Raltegravir Plus Boosted Darunavir Is Safe and Effective for First-line ART

A NRTI-sparing initial regimen of raltegravir (Isentress) plus boosted darunavir (Prezista) worked as well as traditional antiretroviral therapy containing tenofovir/emtricitabine (the drugs in Truvada), according to findings from the NEAT 001 study reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

CROI 2014: Long-acting GSK744 Protects Monkeys against HIV-like Virus [VIDEO]

A long-acting injectable formulation of the next-generation integrase inhibitor GSK1265744 protected monkeys from infection via vaginal or anal exposure to a hybrid human-simian virus, according to 2 studies presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. These promising findings suggest this may be a future approach to pre-exposure prophylaxis (PrEP).

alt

CROI 2014: HIV Transmission through Condomless Sex [VIDEO]

An analysis of more than 750 serodiscordant heterosexual and gay couples in the PARTER study who engaged in more than 45,000 condomless sex acts found no cases of linked HIV transmission when the positive partner was on effective antiretroviral therapy (ART), confirming that treatment as prevention works, according to a report at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

CROI 2014: Mississippi Child Remains Free of HIV [VIDEO]

The "Mississippi Baby" -- now a toddler -- still has undetectable HIV viral load 2 years after interrupting antiretroviral therapy (ART) started within hours after birth, Deborah Persaud reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. Another baby in Los Angeles also appears potentially free of HIV, but this child is still on treatment. 

alt

[Deborah Persaud,CROI press conference, March 4, 2014]

Persaud, from Johns Hopkins University School of Medicine, made asplash at last year's CROI when she reported on an infant born to an HIV positive mother who had not taken prophylactic antiretrovirals to prevent mother-to-child transmission. Given the high-risk situation, the baby was started on combination ART within 30 hours after birth. After 18 months of treatment, the girl's guardians removed her from care and she stopped ART. But when she returned to care several months later, she still had undetectable viral load.

This year Persaud reported that the girl still has undetectable plasma viral load, and extensive testing has not found HIV RNA in peripheral blood cells or resrevoirs. Traces of HIV DNA have been detected, but not replication-competent virus. Persaud and colleagues conclude that the child remains in remission from HIV while off ART, suggesting that very early therapy for infants may lead to a "functional cure."

Persaud also described a second baby in Los Angeles County who also started treatment very early and appears not to have detectable HIV using the most sensitive tests. This child, however, was never taken off antiretroviral treatment, so does not yet represent another potential cure.

3/5/14

Reference

D Persaud, A Deveikis, H Gay, et al. Very Early Combination Antiretroviral Therapy in Perinatal HIV. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 3-6. Abstract 75LB.

CROI 2014: HIV Treatment as Prevention Works in PARTNER Study

No cases of linked HIV transmission were seen during 44,500 condomless sex acts by more than 750 heterosexual and gay couples, according to findings from the PARTNER study presented this week at the Conference on Retroviruses and Opportunistic Infections (CROI 2014).

Treatment as Prevention Dramatically Lowers HIV Sexual Transmission [Press conference video]

No One with Undetectable Viral Load Transmits HIV in PARTNER Study [Study summary]

HIV Transmission through Condomless Sex [Interview with Jens Lundgren]

3/5/14

alt

CROI 2014: HIV Attachment Inhibitor BMS-663068 Shows Good Safety and Efficacy in Phase 2b

Combination therapy using a novel HIV attachment inhibitor demonstrated good safety and effectiveness, offering the promise of a new antiretroviral class that may be particularly beneficial for people with extensive resistance to current drugs, according to a report at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt